Model-Based Characterization of the Bidirectional Interaction between Pharmacokinetics and Tumor Growth Dynamics in Patients with Metastatic Merkel Cell Carcinoma Treated with Avelumab

2021 ◽  
pp. clincanres.2662.2021
Author(s):  
Ana-Marija Grisic ◽  
Wenyuan Xiong ◽  
Lénaïg Tanneau ◽  
Siv Jönsson ◽  
Lena E. Friberg ◽  
...  
2014 ◽  
Vol 50 ◽  
pp. 12
Author(s):  
M.J. Wick ◽  
J. Meade ◽  
M. Nehls ◽  
T. Vaught ◽  
J. Carlile ◽  
...  

2014 ◽  
Vol 2014 ◽  
pp. 1-9 ◽  
Author(s):  
Matthew S. Ning ◽  
Annette S. Kim ◽  
Nripesh Prasad ◽  
Shawn E. Levy ◽  
Huiqiu Zhang ◽  
...  

MicroRNAs have been implicated in various skin cancers, including melanoma, squamous cell carcinoma, and basal cell carcinoma; however, the expression of microRNAs and their role in Merkel cell carcinoma (MCC) have yet to be explored in depth. To identify microRNAs specific to MCC (MCC-miRs), next-generation sequencing (NGS) of small RNA libraries was performed on different tissue samples including MCCs, other cutaneous tumors, and normal skin. Comparison of the profiles identified several microRNAs upregulated and downregulated in MCC. For validation, their expression was measured via qRT-PCR in a larger group of MCC and in a comparison group of non-MCC cutaneous tumors and normal skin. Eight microRNAs were upregulated in MCC: miR-502-3p, miR-9, miR-7, miR-340, miR-182, miR-190b, miR-873, and miR-183. Three microRNAs were downregulated: miR-3170, miR-125b, and miR-374c. Many of these MCC-miRs, the miR-183/182/96a cistron in particular, have connections to tumorigenic pathways implicated in MCC pathogenesis.In situhybridization confirmed that the highly expressed MCC-miR, miR-182, is localized within tumor cells. Furthermore, NGS and qRT-PCR reveal that several of these MCC-miRs are highly expressed in the patient-derived MCC cell line, MS-1. These data indicate that we have identified a set of MCC-miRs with important implications for MCC research.


2002 ◽  
Vol 101 (2) ◽  
pp. 137-145 ◽  
Author(s):  
Mireille Van Gele ◽  
J. Helen Leonard ◽  
Nadine Van Roy ◽  
Heidi Van Limbergen ◽  
Simon Van Belle ◽  
...  

1993 ◽  
Vol 6 (1) ◽  
pp. 65
Author(s):  
Tadashi Karashima ◽  
Hiroshi Hachisuka ◽  
Yoichiro Sasai

2019 ◽  
Vol 65 (3) ◽  
pp. 462-472 ◽  
Author(s):  
Sabine Riethdorf ◽  
Lina Hildebrandt ◽  
Lucie Heinzerling ◽  
Ellen Heitzer ◽  
Nicole Fischer ◽  
...  

Abstract BACKGROUND Merkel cell carcinoma (MCC) is a rare, aggressive skin cancer with increasing incidence and high mortality rates. MCC has recently become the subject of immune checkpoint therapy, but reliable biomarkers for estimating prognosis, risk stratification, and prediction of response are missing. METHODS Circulating tumor cells (CTCs) were detected in peripheral blood from patients with MCC by use of the CellSearch® system. Moreover, CTCs of selected cases were characterized for Merkel cell polyomavirus (MCPyV), chromosomal aberrations, and programed death ligand 1 (PD-L1) production. RESULTS Fifty-one patients were tested at first blood draw (baseline), and 16 patients had 2 or 3 consecutive measurements to detect CTCs. At baseline, ≥1 CTC (range, 1–790), >1, or ≥5 CTCs/7.5 mL were detected in 21 (41%), 17 (33%), and 6 (12%) patients, respectively. After a median follow-up of 21.1 months for 50 patients, detection of CTCs correlated with overall survival (≥1, P = 0.030; >1, P < 0.020; and ≥5 CTCs/7.5 mL, P < 0.0001). In multivariate Cox regression analysis, the detection of ≥5 CTCs/7.5 mL adjusted to age and sex compared to that of <5 was associated with a reduced overall survival (P = 0.001, hazard ratio = 17.8; 95% CI, 4.0–93.0). MCPyV DNA and genomic aberrations frequently found in MCC tissues could also be detected in single CTCs. Analyzed CTCs were PD-L1 negative or only weakly positive. CONCLUSIONS The presence of CTCs is a prognostic factor of impaired clinical outcome, with the potential to monitor the progression of the disease in real time. Molecular characterization of CTCs might provide new insights into the biology of MCC.


1993 ◽  
Vol 6 (1) ◽  
pp. 65
Author(s):  
Hikaru Eto ◽  
Kohzoh Yonemoto ◽  
Takao Fujimura ◽  
Yuko Hamada ◽  
Shigeo Nishiyama ◽  
...  

Oncotarget ◽  
2015 ◽  
Vol 7 (6) ◽  
pp. 6576-6592 ◽  
Author(s):  
Aarthi Kannan ◽  
Zhenyu Lin ◽  
Qiang Shao ◽  
Stephanie Zhao ◽  
Bin Fang ◽  
...  

2020 ◽  
Vol 140 (7) ◽  
pp. S13
Author(s):  
R. Yang ◽  
E.E. Lee ◽  
S. Willcox ◽  
J. Kim ◽  
C. Sullivan ◽  
...  

2001 ◽  
Vol 187 (3) ◽  
pp. 386-391 ◽  
Author(s):  
Konstantin Krasagakis ◽  
Brigitte Almond-Roesler ◽  
Christoph Geilen ◽  
Sabine Fimmel ◽  
Sven Krengel ◽  
...  

Sign in / Sign up

Export Citation Format

Share Document